Long-term budesonide orodispersible tablets effectively maintained remission in patients with eosinophilic esophagitis and demonstrated a favorable safety profile.

The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...

A recent novel study published in the New England Journal of Medicine found that Depemokimab can reduce asthma exacerbations in patients with the eosinophilic phenotype. Improperly controlled asthma ...

bronchial asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD). It was also under development for the treatment of severe atopic dermatitis and eosinophilic fasciitis.

Emphysema did not significantly affect the response to systemic therapy in patients with severe asthma, according to a recent retrospective study. Early improvement was linked to lower baseline FEV1 ...

Daily or Twice Daily Treatment with Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis. In Clinical Gastroenterology ... Metoprolol Safer Beta Blocker for Asthma Patients, ...

Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a ...

04 November 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June ...

TUESDAY, Dec. 10, 2024 (HealthDay News) — Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The ...